Showing results (51-60 of 61) with videos related to

Sort By:
Pageof 7
The Journal of Clinical Psychiatry|February 1, 1984
Double-blind comparison of amoxapine and imipramine in the treatment of depressed patientsA J Gelenberg, J D Wojcik, R B Lydiard, et al.
Drug and Alcohol Dependence|September 22, 2009
Case histories in pharmaceutical risk managementCynthia G McCormick, Jack E Henningfield, J David Haddox, et al.
Journal of Hepatology|August 15, 2015
Treating liver fat and serum triglyceride levels in NAFLD, effects of PNPLA3 and TM6SF2 genotypes: Results from the WELCOME trialEleonora Scorletti, Annette L West, Lokpal Bhatia, et al.
Drug and Alcohol Dependence|April 4, 2006
Impact of formulation on the abuse liability, safety and regulation of medications: the expert panel reportCharles Grudzinskas, Robert L Balster, Charles W Gorodetzky, et al.
ACS Nano|January 22, 2010
Investigating the outskirts of Fe and Co catalyst particles in alumina-supported catalytic CVD carbon nanotube growthMark H Rümmeli, Franziska Schäffel, Alicja Bachmatiuk, et al.
Cells|March 29, 2023
BAG3: Nature's Quintessential Multi-Functional Protein Functions as a Ubiquitous Intra-Cellular GlueCaitlyn M Brenner, Muaaz Choudhary, Michael G McCormick, et al.
Ophthalmic Plastic and Reconstructive Surgery|October 3, 2020
Diplopia Following the Insertion of a Canalicular Bypass Tube: Etiology, Risk Factors, Management, and OutcomesJohn C Bladen, Ilse Mombaerts, Hirohiko Kakizaki, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|November 23, 2025
Safety and Efficacy of Atezolizumab in Combination With nab-Paclitaxel in Patients With PD-L1 Positive Metastatic or Locally Advanced Triple-Negative Breast Cancer: A UK-Wide Cancer Centre ExperienceJ V Waterhouse, A Holdich, F Mina, et al.
JACC. Basic to Translational Science|August 7, 2023
Bag3 Regulates Mitochondrial Function and the Inflammasome Through Canonical and Noncanonical Pathways in the HeartJuFang Wang, Dhadendra Tomar, Thomas G Martin, et al.
Leukemia|November 9, 2007
Phase I/II study of gemtuzumab ozogamicin added to fludarabine, melphalan and allogeneic hematopoietic stem cell transplantation for high-risk CD33 positive myeloid leukemias and myelodysplastic syndromeM de Lima, R E Champlin, P F Thall, et al.
Pageof 7